FRC
FRC Logo
Sign InGet Access

Connect With Us

Stay updated with our latest research and insights

Fundamental Research Corp Logo

Highly ranked equity research firm providing institutional grade tools and analysis to all investors worldwide. Trusted by global investors for over 20+ years.

20+ Years

Policies

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Company

  • About Us
  • Our Team
  • Contact Us

Resources

  • Videos
  • Research Reports
  • FAQ

© 2026 Fundamental Research Corp. All Rights Reserved.

Professional investment research since 2003

Home
Research
Get Access
Sign In
Rani Therapeutics Holdings, Inc. Stock AnalysisComprehensive stock analysis for Rani Therapeutics Holdings, Inc. (RANI) including live price, Snowflake performance metrics, financial statements, and investment research.Stock AnalysisRANI
RANI
Rani Therapeutics Holdings, Inc.
  • Company Overview
  • FRC Research
  • Financial Data
  • Peer Comparison
  • Ownership & News
RANI
Home🔹Stocks🔹Rani Therapeutics Holdings, Inc.

Rani Therapeutics Holdings, Inc.

RANI•NASDAQ

Rani Therapeutics Holdings, Inc.

RANI•NASDAQ
Market cap
$55.58M
Sentiment

Your view on RANI

Mkt Cap
$55.58M
Sentiment
Your view
RANI
Rani Therapeutics Holdings, Inc.
  • Company Overview
  • FRC Research
  • Financial Data
  • Peer Comparison
  • Ownership & News
RANI
Company Overview

Overview

What the company does, where it operates, and who runs it.

About Rani Therapeutics Holdings, Inc.

Industry
Biotechnology
Sector
Healthcare
CEO
Talat Imran
Headquarters
2051 Ringwood Avenue, San Jose, CA, US
Industry
Biotechnology
Sector
Healthcare
CEO
Talat Imran
Headquarters
2051 Ringwood Avenue, San Jose, CA, US
Description

Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics. The company develops the RaniPill capsule, a platform that is intended to replace subcutaneous or IV injection of biologics with oral dosing. Its product pipeline includes RT-101, an octreotide, which has completed Phase I clinical trial for the treatment of neuroendocrine tumors and acromegaly; RT-105, an anti-TNF-alpha antibody to treat psoriatic arthritis; RT-102, a parathyroid hormone that is in preclinical studies for the treatment of osteoporosis; RT-109, a human growth hormone to treat growth hormone deficiency; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; and RT-106, a basal insulin for the treatment of type 2 diabetes. The company was incorporated in 2012 and is headquartered in San Jose, California.

Infographics

Visual summary of the business at a glance.

FRC Research

Media

Videos and interviews covering the company.

Financial Data

Stock Data

Price chart, volume, and trading data.

Fair Value

What FRC thinks the stock is worth vs. the current price.

Financial Ratios

Profitability, returns, valuation, and leverage ratios.

Dividend Analysis

Yield, payout ratio, and dividend coverage metrics.

Earnings Analysis

EPS history, beat rate, and upcoming earnings reports.

Financial Statements

Income statement, balance sheet, and cash flow statements.

Peer Comparison

Comparables

List of peer companies in the same industry.

Ownership & News

Institutional Ownership

Which funds and firms own the stock.

Insider Trading

Recent buying and selling by company executives.

Senate Trading

U.S. Senator disclosures filed under the STOCK Act.

News

Latest headlines and market coverage.

News

Latest Market News